期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

大剂量阿托伐他汀治疗冠心病调脂效果的观察 被引量：11

下载PDF
导出
摘要 目的:观察阿托伐他汀剂量对冠心病强化降脂的疗效及安全性。方法:选择96例45～75岁的冠心痛患者合并高脂血症患者,随机分为二组:在常规冠心病治疗基础上(包括肠溶阿司匹林、硝酸脂类、8-受体阻滞剂),A组46例使用阿托伐他汀20mg,B组50例使用阿托伐他汀40mg。治疗4周、8周后分别作血液检查,观察调脂疗效、肝肾功能损害、肌溶解等不良反应。结果:治疗6周时,20mg/d和40mg/d组间及治疗前TC-C下降明显差异(P<0.05),有统计学意义。两组达标率比较,不同剂量阿托伐他汀在治疗6周及12周后TC、LDL-C达标差异有统计学意义(P<0.05)。说明阿托伐他汀40mg可显著提高血脂达标率,疗效与剂量相关。结论:对于冠心病合并高血脂症患者,强化降脂治疗(阿托伐他汀40mg)安全有效,不良反应较少,能提高达标率,减少心血管事件。
作者 刘咏梅
机构地区 集中能源峰峰集团牛儿庄矿医院内科
出处 《贵阳中医学院学报》 2013年第2期88-90,共3页 Journal of Guiyang University of Chinese Medicine
关键词 强化降脂 冠心病 阿托伐他汀
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献6

二级参考文献32

  • 1Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 subjects with coronary heart disease: The Scandinavian Simvastatin Survival Study(4S). Lancet,1994,344:1383-1389. 被引量：1
  • 2Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA,1998,279:1615-1622. 被引量：1
  • 3He J, Gu D, Reynolds K, et al. Serum total and lipoprotein cholesterol levels and awareness, treatment, and control of hypercholesterolemia in China. Circulation,2004,110:405-411. 被引量：1
  • 4Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ) .Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.JAMA,2001,285:2486-2497. 被引量：1
  • 5Heart Protection Study Collaborative Group. MRC.BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomised placebo controlled trial. Lancet, 2002,360:7-22. 被引量：1
  • 6Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ guidelines. Circulation, 2004 ,110: 227-239. 被引量：1
  • 7Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes:a randomised placebo-controlled trial[J]. Lancet ,2003,361:2005-2016. 被引量：1
  • 8Sever PS,Dahlof B, Poulter NR,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) : a multicenter randomized controlled trial[J]. Lancet,2003,361:1149-1158. 被引量：1
  • 9Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention[J]. Circulation ,2003,107:363-369. 被引量：1
  • 10Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events[J]. N Engl J Med,2002,347:1557-1565. 被引量：1

共引文献358

同被引文献76

  • 1陈懿,徐世鄂.瑞舒伐他汀和阿托伐他汀对冠心病患者的调脂作用和安全性比较[J].中国老年学杂志,2014,34(9):2389-2390. 被引量：93
  • 2唐慧,关林,姜国攀.强化降脂对冠心病患者的疗效及安全性[J].中国热带医学,2007,7(2):223-223. 被引量：2
  • 3Tikkanen MJ,Fayyad R,Faergeman Q,et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase Ievels[J]. Int J CardioI, 2013, 168(4) :3846-3852. 被引量：1
  • 4Pitt B, Loscalzo J, Monyak J, et al. Comparison of lipid-modif- ying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study)[J]. Am J Cardiol , 2012,109(9) :1239-1246. 被引量：1
  • 5Wagner M, Goetghebeur M, Merikle E, et al. Cost-effective- ness of intensive lipid lowering therapy with 80 mg of atorvasta- tin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada[J]. Can J Clin Pharmaeol, 2009,16(2) :331-345. 被引量：1
  • 6Rossen VM, Taylor DC, Parekh H, et al. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US[J]. Phar- macoeconomics, 2010,28 (1) : 47-60. 被引量：1
  • 7王武林,唐玫琴,唐新华,王琦.冠心病疾病危险因素的分布与分析[J].实用预防医学,2007,14(6):1916-1917. 被引量：6
  • 8杨慧,王福生.他汀类药物在治疗急性冠脉综合征患者中应用新进展[J].中国保健营养(上旬刊),2014,24(7):4548-4549. 被引量：1
  • 9沈学锋.探讨他汀类药物在冠心病调脂治疗中的作用与方法[J].世界最新医学信息文摘(连续型电子期刊),2014,14(36):28.30. 被引量：1
  • 10Nakamura H, Arakawa K, Itakura H, et al. Primary Prevention of car- diovas-cular diseasa with Pravastatin in Japan ( MEGA Study ) :apro- spective randomized controlled trial [J].. Lancet, 2006,368 ( 9542 ) : 1155 - 1163. 被引量：1

引证文献11

二级引证文献51

贵阳中医学院学报
2013年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部